Agomab is a Belgian-headquartered biotech company developing a portfolio of unique small molecule compounds and antibodies that address the transforming growth factor beta (TGF-\u00df) and hepatocyte growth factor (HGF) pathways. Growth factor pathways play an important role in morphogenesis and tissue repair and are promising targets for addressing tissue injury and fibrotic remodeling in a range of high unmet medical need indications including fibrostenotic Crohn\u2019s disease and idiopathic pulmonary fibrosis.<\/p>\n
\u201cThe Fierce 15 award is a great endorsement of our team\u2019s groundbreaking work and we are thrilled to join an outstanding group of companies that Fierce sees as the up-and-coming vanguard for our industry. This important recognition comes in a transformative year in which we have extended a major financing round, acquired another biotech company and successfully conducted a first-in-human study with our lead compound,\u201d said Tim Knotnerus, Chief Executive Officer at Agomab Therapeutics.<\/strong> \u201cWe are developing a range of highly-innovative product candidates that address well-validated and potentially disease-modifying targets while overcoming the challenges of earlier attempts to target growth factors in fibrosis.\u201d<\/p>\n The Fierce 15 celebrates the spirit of being \u201cfierce\u201d \u2013 championing innovation and creativity, even in the face of intense competition. This is Fierce Biotech\u2019s 20th annual Fierce 15 selection.<\/p>\n An internationally recognized daily report reaching a network of over 450,000 biotech and pharma industry professionals, Fierce Biotech provides subscribers with an authoritative analysis of the day’s top stories. Every year Fierce Biotech evaluates hundreds of early-stage companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.<\/p>\n","protected":false},"excerpt":{"rendered":" Agomab is a Belgian-headquartered biotech company developing a portfolio of unique small molecule compounds and antibodies that address the transforming growth factor beta (TGF-\u00df) and hepatocyte growth factor (HGF) pathways. Growth factor pathways play an important role in morphogenesis and tissue repair and are promising targets for addressing tissue injury and fibrotic remodeling in a…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-16398","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"\n